The European Medicines Agency said on Friday its experts had recommended marketing approval for lung cancer drugs developed by AstraZeneca Plc and Eli Lillyand Co, although approval for AstraZeneca's drug came with conditions.
Europe recommends drugs from AstraZeneca, Lilly
Europe's drugs regulator said AstraZeneca must still provide results from an ongoing late-stage study of its drug, osimertinib, to receive full approval.
Recommended articles
Europe's drugs regulator said AstraZeneca must still provide results from an ongoing late-stage study of its drug, osimertinib, to receive full approval.
The Committee for Medicinal Products for Human Use (CHMP) recommended without conditions Eli Lilly's necitumumab, as well as a second product from AstraZeneca, lesinurad, to treat gout.
The recommendations are good news for AstraZeneca, which has been been under pressure as its older blockbuster products, including cholesterol fighter Crestor and heartburn pill Nexium, lose patent protection.
On Thursday, AstraZeneca said it would buy a majority stake in privately held biotech firm Acerta Pharma to gain access to a new kind of blood cancer drug.
JOIN OUR PULSE COMMUNITY!
Eyewitness? Submit your stories now via social or:
Email: eyewitness@pulse.ng